Incannex Healthcare (IXHL) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
28 Oct, 2026Executive summary
Annual meeting set for Dec. 17, 2026, at 10:00 AM Gulf Standard Time; meeting will be held virtually.
Proxy materials and annual report are available online; paper or email copies may be requested by Dec. 10, 2026.
Voting matters and shareholder proposals
Proposal 1 seeks election of two Class III directors for three-year terms expiring in 2029; the Board recommends FOR both nominees.
Proposal 2 seeks ratification of Grant Thornton Audit Pty Ltd as independent registered public accounting firm for FY ending June 30, 2027; the Board recommends FOR.
Board of directors and corporate governance
Joel Latham and Troy Valentine are nominated for election as Class III directors for terms expiring in 2029.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Incannex Healthcare
- DREAMzz dosing advanced as quarterly losses narrowed, but a control weakness persists.IXHL
Q1 2027 - Two director elections and auditor ratification anchor the Dec. 17 virtual meeting.IXHLProxy filing
- Clinical investment grew; $14.55m cash was forecast to fund operations through Dec. 2024.IXHLQ2 2024
- Net loss improved to $19.3M, cash rose to $67.7M, and lead clinical programs advanced.IXHLQ4 2026
- Cash rose to $74.5M, net loss reached $16.8M, and $9.1M was spent on share repurchases.IXHLQ3 2026
- Late-stage oral therapies for OSA, GAD, and RA show strong efficacy and safety in Phase 2 trials.IXHLInvestor presentation
- Net loss reached $12.9M, cash rose to $68.9M, and 3.1M shares were repurchased.IXHLQ2 2026
- Annual meeting adjourned and rescheduled due to auditor proposal classification issue.IXHLProxy Filing
- Net loss widened to $5.4M as cash fell to $3.6M, with new financings offsetting going concern risks.IXHLQ1 2025